Review of oral cholera vaccines: efficacy in young children
Cristina Masuet Aumatell1, JM Ramon Torrell1, Jane N Zuckerman2
1International Health Centre, Preventive Medicine Department, Bellvitge Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; 2World Health Organization Collaborating Centre for Reference, Research and Training in Travel Medicine, University College London Medical School, London, UK
Background: Young children are one of the most vulnerable groups who may be infected with cholera. The following literature review of the efficacy of the currently available cholera vaccines provides a clear evidence base for the clinical administration of cholera vaccine, particularly in an epidemic situation.
Aim: To assess the efficacy of oral cholera vaccines in preventing cases of cholera in young children.
Methods: A systematic literature review was undertaken for the period 1983 to 2011 using PubMed and the search terms “oral cholera vaccines,” “children,” and “efficacy,” limited to “clinical trials” and “human studies”.
Results: Oral cholera vaccine provides an acceptable level of protection in young children, with the level of protection being greater at 12 or 24 months following immunization.
Conclusions: Children exposed to a potential risk of cholera are recommended to be vaccinated with an oral cholera vaccine, irrespective of whether its constituents include the B subunit.
Keywords: efficacy, oral cholera vaccine, children
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Phosphodiesterase inhibition in the treatment of autoimmune and inflammatory diseases: current status and potential
Published Date: 23 December 2014
Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights
Schalper KA, Venur VA, Velcheti V
Published Date: 23 December 2014
Wong AWY, Zhang C, Chu CH
Published Date: 8 May 2014
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C
Published Date: 27 March 2014
Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T
Published Date: 19 March 2014
Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H
Published Date: 4 March 2014
Gao B, Doan A, Hybertson BM
Published Date: 3 February 2014
Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance
Chen LF, Anderson DJ, Paterson DL
Published Date: 24 September 2012
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG
Published Date: 7 October 2011
Published Date: 18 August 2011